Less Invasive Surfactant Administration via Thin Catheter in Late Preterm Infants with Respiratory Distress Syndrome

Abstract


Procedures
LISA procedure involved the use of a laryngoscope to place the thin catheter beyond the vocal cords to the required depth.Once the catheter was correctly positioned, poractant alfa was dosed at 200 mg/kg for the first dose and then at 100 mg/kg every 6-8 hours, for up to 2 additional doses, while maintaining nCPAP or nIPPV.Surfactant administration was divided into slow boluses of 0.5 ml each administered through the catheter, according to the patient tolerability.During and after surfactant instillation, aspiration of gastric contents was performed to confirm whether surfactant reached the lungs effectively, and if an additional surfactant administration was required.
Premedication administered in newborns of less than 35 weeks' gestation included atropine and caffeine, to reduce the frequency of apnea of prematurity.Various nonpharmacological methods were used as analgesic measures to alleviate pain in neonates, such as oral sucrose, non-nutritive sucking, and contention measures.Pharmacological methods included the administration of the anesthetics propofol (0.5 mg/kg), morphine, and ketamine (1 mg/kg), when needed.

Data recording
Maternal and neonatal data, collected retrospectively from the medical records, included sex, gestational age, birth weight, intrauterine growth retardation cases, multiple birth, type of delivery (eutocic, C-section or instrumental); Apgar score at 1, 5 and 10 minutes; need for cardiopulmonary resuscitation intervention with nCPAP or nIPPV; maternal age, prenatal corticosteroids, vertical sepsis, maternal gestational pathologies, first admission unit (intermediate neonatal care unit or NICU); type of NIV before LISA (nCPAP or nIPPV); FiO 2 before and at 1, 6, 24, 56 and 72 h after surfactant treatment; pCO 2 and pH values obtained from capillary blood gas measurements before LISA; chronological age at surfactant administration; number of surfactant doses administered; drug administration before or during LISA (atropine, caffeine, and/or sedative medications); desaturation events during LISA (mild: SpO 2 80-89%; moderate: SpO 2 60-80%; severe SpO 2 <60%; NIV duration; need for invasive mechanical ventilation (IMV) after LISA; neonatal morbidities such as BPD, necrotizing enterocolitis (NEC) and intraventricular hemorrhage (IVH); final diagnosis; duration of NICU stay; and duration of neonatal hospital stay.

Statistical analysis
Descriptive statistics were generated for all data.Continuous variables were described using the median and range (described by the minimum and maximum values of the variables).Categorical variables were described as absolute (n) and relative (%) frequencies.All statistical analyses were performed using SPSS version 20.0.

Background
Respiratory distress syndrome (RDS), also known as hyaline membrane disease, is the most common respiratory disorder experienced by premature infants, as well as the leading cause of neonatal respiratory morbidity and mortality [1].The condition is caused by lack of surfactant in the lungs, which leads to atelectasis, decreased gas exchange and hypoxia [2].The incidence of RDS decreases with advancing gestational age, from about 60-80% in babies born at 26-28 weeks, to about 15-30% in those born at 32-36 weeks [3,4].Among premature newborns, late preterm infants -those born between 34 0/7 and 36 6/7 weeks of gestation-account for approximately 70% of all preterm births [5,6].Although these infants have been historically considered to be developmentally as mature as term newborns, they are known to be structurally and functionally immature, and have significantly higher rates of mortality and respiratory morbidities, such as RDS, than term infants [7][8][9][10].Management of RDS is therefore primarily focused on providing appropriate respiratory support to maximize survival while reducing potential complications.
Surfactant therapy is a well-established therapy for RDS in preterm neonates [11,12] and plays an essential role in the management of RDS in late preterm infants [13,15].Administration of surfactant can be performed by standard endotracheal intubation, requiring experienced practitioners, or through less invasive surfactant administration (LISA) techniques, also referred to as MIST (Minimally Invasive Surfactant Therapy).The most commonly utilized LISA technique involves the use of a thin catheter, which is being used as a non-invasive alternative to the standard mode of surfactant delivery [11,[15][16][17][18][19].This technique is becoming widely employed in neonatal intensive care units (NICU) worldwide [20][21][22], since it reduces the need for mechanical ventilation and decreases the risk of bronchopulmonary dysplasia (BPD) in preterm infants [15,[23][24][25][26].However, research has been mainly focused on very premature infants, and the potential benefit of surfactant administration using LISA procedure in late preterm neonates requires further investigation.In this study, we investigated the tolerability and the effects of the use of LISA through a thin catheter in late preterm infants with RDS admitted to our NICU.

Study design and participants
This was a retrospective, single-center, observational study conducted between June 2017 and March 2020, in a level III NICU at Virgen de la Arrixaca University Hospital in Murcia (Spain).
Patients that met the following criteria were included: preterm infants between 34 0/7 and 36 6/7 weeks of gestation with clinical and radiographic evidence of neonatal RDS that required non-invasive ventilation (NIV) as initial support, provided with either nasal continuous positive airway pressure (nCPAP) or nasal intermittent positive pressure ventilation (nIPPV); patients requiring a fraction of inspired oxygen (FiO 2 ) ≥30% and with a positive end-expiratory pressure (PEEP) of 6 cm of H 2 O to maintain an oxygen

Results
The number of patients included was 20, who represented the 33.3% of all late preterm neonates with respiratory failure that required NIV and who were admitted to our NICU during the study period.Demographic and clinical characteristics of mothers and preterm infants receiving surfactant with LISA technique are shown in table 1.The mean gestational age was 35 (34 1/7 -36 6/7 ) weeks.Seven infants (35.0%) received prenatal corticosteroids for fetal lung maturation.Mothers had a mean age of 31.0  years and only one of them presented an underlying medical condition (HELLP syndrome).The most frequent type of delivery was C-section (15/20, 75.0%), and the multiple birth rate was 35.0%(7/20).Only three preterm infants (15.0%) were hospitalized on the first day of admission at the NICU, whereas the rest of neonates (17/20, 85.0%) were admitted to an intermediate neonatal care unit.Ten newborns (50.0%) required resuscitation to breathe with nCPAP or nIPPV, although no signs of acute fetal distress were observed (all births had a 5 min Apgar score >5).Mean pCO 2 , pH and FiO 2 values before LISA were 53 (40-81) mmHg, 7.28 (7.19-7.48),and 0.41 (0.3-0.6), respectively.Before LISA, thirteen patients (13/20, 65.0%) were treated with nCPAP and seven (7/20, 35.0%) with nIPPV.Premedications used before or during LISA were caffeine, which was administered to 50.0% (10/20) of infants; and ketamine or morphine sedation, in 20.0% (4/20) of cases.
Table 2 summarizes the characteristics of surfactant administration with LISA and the respiratory evolution of the preterm infants.The mean age at surfactant administration was 22 (2-48) hours of life.A LISAcath® catheter was used in 85% (17/20) of patients, whereas a vascular catheter was used in the rest of cases (15%, 3/20).
Figure 1 shows the evolution of FiO 2 levels with timebefore and up to 72 h after surfactant administration-and the percentage of patients that reached a FiO 2 value of 0.21 at each time point.Median FiO 2 prior to administration of surfactant was 0.36.One hour after the procedure, half of infants reached a FiO 2 of 0.21, and 9 of them had a FiO 2 ≤ 0.35 before LISA.The percentage of patients that reached a FiO 2 of 0.21 increased to 70.0% at 6 h post-administration.The vast majority of patients (90.0%) reached FiO 2 0.21 after 56 h, remaining at this value after 72 h of instillation except for one infant, whose FiO 2 increased to 0.30 probably because NIV was discontinued.
The mean time on NIV was 70 (24-168) hours.Overall, the final diagnosis was RDS in 18 (90.0%)infants, one congenital pneumonia (5.0%) and one pulmonary interstitial glycogenosis (5.0%).None of the patients with a final diagnosis of RDS required IMV.In addition, no severe comorbidities as well as no deaths occurred.The non-RDS patients improved their condition after surfactant administration, with a decrease in FiO 2 requirement, although improvement was transient and not sustained.The only infant requiring IMV was the one diagnosed with congenital pneumonia.The intrauterine growth-retarded infant was diagnosed with periventricular leukomalacia of prenatal origin in the first cerebral ultrasound at 3 days of life.The mean duration of NICU stay was 6 (2-23) days and the mean duration of hospital stay was 17  days.

Discussion
In this retrospective study, we assessed the effectiveness and tolerability of surfactant administration using the LISA technique in late preterm infants diagnosed with RDS.Among all preterm newborns, half of them required resuscitation with nCPAP or nIPPV as initial respiratory support.Although these patients experienced difficulties during transition from intrauterine to extrauterine life, none of them had signs of acute fetal distress.Nonetheless, only three infants (15.0%) were hospitalized on the first day of admission at NICU, indicating a late RDS detection in the preterm newborns first admitted to an intermediate neonatal care unit.This fact emphasizes the importance of finding alternative methods for the diagnosis of RDS that are not based exclusively on clinical features and radiographic findings.On the other side, this would explain the initial higher FiO 2 values and mean chronological age at surfactant administration of those preterm newborns first admitted to an intermediate neonatal care unit, as compared to the rest of preterm infants admitted to the NICU (mean FiO 2 : 0.40 versus 0.37; mean age: 22 versus 8.5 h).
After surfactant administration using LISA, we found an important and sustained improvement of the respiratory function in the vast majority of patients, as evidenced by the decrease in FiO 2 to 0.21 at 24 h in 85% of infants.

ISSN: 2581-7493
On the other side, patients with a final diagnosis of RDS did not require NIV after surfactant treatment.Despite the fact that two patients were clinically misdiagnosed with RDS, LISA procedure did not have any negative impact on them.On the contrary, FiO 2 levels were reduced after LISA, and IMV was only required in one of the cases -the preterm newborn diagnosed with congenital pneumonia-.The infant diagnosed with pulmonary glycogenosis did not require IMV, except to perform lung biopsy, through which the definitive diagnosis was made.However, the observed clinical improvements were transient and clinicians suspected that patients could have been initially misdiagnosed with RDS.Again, these observations highlight the need for a correct diagnosis of RDS, not only based on radiological findings and clinical course.We believe that the use of thoracic ultrasonography, which is considered an accurate and reliable tool in the diagnosis of RDS in the newborn [27,28], could help early and rigorous diagnosis of the disease.
While the efficacy of surfactant therapy has been reported to improve respiratory function in late preterm infants with RDS [13,29,30], surfactant administration by minimally invasive methods is still being investigated in this population.The LISA method via thin catheter is widely adapted in Europe [31] and is a recommended method of care according to the latest consensus guidelines [11,15,32].However, there is still large variability in the application of this technique regarding patient population that may benefit from this approach; the catheter type, the adequate dose and type of surfactant; the use of premedication; and the need of pharmacologic sedation during the procedure [33].A meta-analysis conducted by Lau et al. [18] provides a comprehensive review of the use of LISA via thin catheter in preterm infants.Overall, the authors underline -as reported in previous works [17,24,34,35]-the suitability of this technique in preterm infants.However, additional studies are required to address the infant selection issue in this vulnerable population.While the mentioned studies recommend the use of LISA in preterm infants, their outcomes should not be extrapolated to a different pediatric age range or other specific age subgroups.Up to date, there is only one study reporting on the use of LISA in moderate and late preterm neonates between 32 0/7 and 36 6/7 weeks [36].The authors compared standard RDS management (surfactant administration given only after intubation) with LISA procedure.Their results showed a reduction in mechanical ventilation exposure and RDS complications as compared to standard therapy.In our study, the LISA procedure performed on late preterm infants appeared to be of benefit for this particular subgroup of premature babies, with no need for IMV after LISA, thus reducing its associated complications.Furthermore, the adverse events documented during LISA were low, with mainly mild to moderate desaturations and a small rate of surfactant reflux, indicating that surfactant delivery was optimal for the vast majority of patients [37].
The positive respiratory outcomes of surfactant treatment with LISA technique and the low frequency of acute side effects observed in this study could respond to various factors, such as the type of the catheter used; the type, dose, and volume of the surfactant administered; the use of premedication; and the extensive experience of our neonatologists performing LISA procedure.The type of catheters utilized for surfactant delivery were LISAcath® or semirigid vascular catheters, which are easier to handle, do not require Magill forceps, and lower the risk of injuries in premature infants.In relation to the effect of the surfactant, it has been reported that the size of the first dose may be more important for clinical response than the source of surfactant [38].In our study, the initial dose of poractant alfa was 200 mg/kg, which has been shown to lead to a lower risk for complications than an initial dose of 100 mg/kg [38,39].Higher first doses of surfactant also reduce the need for repeat doses [40,41], as shown in a study conducted in preterm infants <35 weeks gestation with RDS that required fewer additional doses of poractant alfa (200 mg/kg) as compared to beractant (100 mg/kg) [42].Our findings are in accordance with these observations, since surfactant redosing was only required in one of the late preterm infants diagnosed with RDS.Exposure to antenatal corticosteroids also seemed to be associated with a low risk of procedural complications, as observed by either the absence of problems or a mild decrease in oxygen saturation during LISA.In addition, all but one of these patients reached a FiO 2 of 0.21 after surfactant treatment.In fact, as it has been reported, administration of steroids in mothers at risk of late preterm delivery has been attempted with promising results in terms of a decreased need for respiratory support and oxygen [37].
Regarding the use of medications during the procedure, sedation and analgesia were administered at the discretion of each neonatologist, since there are not established protocols in our unit.In fact, administration of sedation and analgesia are controversial issues in RDS management [43].More specifically, sedation for LISA is complex, because while low-dose sedation prior to laryngoscopy is technically attainable and makes the baby less uncomfortable, it increases the risk of CPAP failure.Thus, there is no clear consensus on whether or not to sedate routinely for LISA, and which sedative to use, leaving these decisions up to clinicians [11].Our neonatologists have the subjective perception that in the absence of pharmacological sedation, technical complications during LISA arise more frequently in late preterm infants than in other premature newborns.
Our conclusions should be considered in light of some intrinsic limitations of the retrospective nature of this study.Secondly, the low sample size and the lack of a control group did not allow us to establish definitive conclusions on the effectiveness and tolerability of the technique, nor to compare outcomes with other modes of surfactant administration.Therefore, the results presented herein should be considered exploratory and interpreted with caution.Future studies with larger sample sizes will be needed to evaluate the benefits of LISA in late preterm infants, as well as to address unresolved questions and clinical issues for its successful implementation.

Conclusion
The results of this study may have relevance to clinical www.innovationinfo.orgISSN: 2581-7493 practice on the effect of the LISA technique via thin catheter in late preterm infants diagnosed with RDS.LISA appeared to be an effective and safe method of surfactant delivery in late premature neonates, improving respiratory outcomes with no need for mechanical ventilation.Moreover, adverse outcomes associated with LISA were low, with mainly mild oxygen desaturations, and a small rate of surfactant reflux and apnea.

Figure 1 :
Figure 1: Evolution of median FiO 2 levels before and after surfactant administration, and percentage of patients that reached a FiO 2 value of 0.21 at each time point.

Table 1 :
Demographic and clinical characteristics of mothers and infants receiving surfactant administration with LISA technique.

Table 2 :
Characteristics of surfactant administration with LISA and respiratory evolution of the late preterm infants.